drugset / Trial / NCT03720873
EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC
NaSingle-groupOpen-labelTreatment
Summary
A single arm study: EGFR-TKIs Combine With Anlotinib as First-line Treatment in patients with EGFR-mutant non-small-cell lung cancer (NSCLC).
Timeline
- Start
- 2018-10
- Primary completion
- 2021-06
- Completion
- 2022-09
Publications
- Results Maemondo M, Fukuhara T, Sugawara S, et al. NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations[J]. Annals of Oncology, 2016, 27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Erlotinib | Small molecule | 150 mg | — |
| Subject | Gefitinib | Small molecule | 250 mg | — |
| Subject | Icotinib | Small molecule | 125 mg | — |
Indications
No indication recorded.